H.R. 3, The Lower Drug Costs Now Act, passed 2 committees in the House of Representatives Thursday, with a bipartisan amendment intended to boost uptake of biosimilars tucked inside.
H.R. 3, The Lower Drug Costs Now Act, passed 2 committees in the House of Representatives Thursday, with a bipartisan amendment intended to boost uptake of biosimilars tucked inside.
At the hearing in the House Energy and Commerce Committee, legislators amended the bill to include a proposal from Representatives Kurt Schrader, D-Oregon, and Greg Gianforte, R-Montana. The change would increase reimbursement for biosimilar drugs in Medicare Part B to the average sales price (ASP) plus 8%, up from the current 6% plus ASP, for 5 years. The idea was introduced last month as a separate bill, the BIOSIM Act.
The bill, which was also passed in the Education and Labor Committee, aims to lower prescription drug costs by giving the federal government the ability to negotiate price based on an international pricing index and sets a $2000 out-of-pocket limit in Medicare Part D.
Another amendment increased the minimum number of drugs that the administration could negotiate from the top 25 most costly drugs to the top 35. And it raised the threshold for drugs that could be subject to HHS negotiations from those with 1 generic competitor to those with 2 generic competitors.
House Speaker Nancy Pelosi, D-California, is moving ahead with the bill despite the communication breakdown with President Donald Trump, who campaigned on lowering drug prices, but is now the subject of an impeachment inquiry, making the bill’s future in the Republican-controlled Senate uncertain.
Pelosi’s bill would force companies to negotiate by imposing strict taxes on the medications if the firms refused. The Congressional Budget Office has estimated the legislation would cut industry revenues by $500 billion to $1 trillion over 10 years, but also save Medicare $345 billion over 7 years, partly because beneficiaries would no longer have to engage in drug rationing, and thus staying healthier.
A separate estimate from HHS found that households would save $158 billion over 10 years.
The House Ways and Means Committee is expected to mark up and vote on the measure next week, setting the bill up for a full House vote during the last week of October, according to reports.
The AARP was one of the organizations testifying in favor of the bill in Ways and Means, which had a hearing Thursday. Last month, the organization released a report saying drug prices have been rising for 12 straight years.
“Simply put, current prescription drug price trends are not sustainable. There is no reason Americans should continue to have to pay the highest brand-name drug prices in the world. No one should be forced to choose between buying groceries and buying the prescription drugs they need. It is long past time for Congress to take action to lower prescription drug prices,” said AARP National Volunteer President Catherine Alicia Georges, EdD, RN, in remarks prepared for testimony.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.